Polaris’ Pandion partners with Astellas on diabetes bispecifics

Formed by Polaris Partners to develop therapies that restore immune homeostasis at the site of disease, Pandion has entered its first large pharma partnership under which it will work with Astellas to discover and develop bispecific antibodies to treat pancreatic autoimmune diseases, including Type I diabetes.

Pandion Therapeutics Inc. will initially receive up to $45 million, which comprises an upfront payment and preclinical milestones. The company is also eligible for about $750 million in development and commercial milestones, plus royalties. ...